Asthma drug meets main goal of study to treat smokers’ lungs
UK drugmaker GSK said its asthma drug Nucala has achieved the primary endpoint of a late-stage study in patients with chronic obstructive pulmonary disease, or smoker’s lung. According to GSK, patients treated with Nucala and maintenance inhaled therapy for 104 weeks had a lower average annual rate of moderate to severe exacerbations than those taking a placebo.
POPULAR POSTS
Bluetongue outbreak in a Portuguese sheep farm has broken out
September 19, 2024
Austria says disaster fund to rise to 1 billion euros
September 19, 2024
Portugal gets help from Spain and Morocco in response to fires
September 19, 2024
Drought reduces Amazon rivers to historic lows
September 19, 2024
LIVE STREAM